Compared to patients treated with antidiabetic drugs (excluding GLP-1 receptor agonists), patients treated only with GLP-1 receptor agonists have been observed to be at increased risk of certain comorbidities, such as (1) cardiovascular disorders (hypotension, syncope), (2) gastrointestinal disorders and pancreatitis, (3) degenerative joint diseases, and (4) nephrolithiasis and interstitial nephritis
Analytical capabilities include advanced testing methods for liposome characterization, purity verification, and stability analysis
Oral semaglutide is co-formulated with the absorption enhancer sodium N -(8-[2-hydroxybenzoyl]amino) caprylate, which facilitates the transcellular absorption of semaglutide across the gastric mucosa [2]
Purpose-built for physicians GLP-1s lower BMI, preserve kidney function for adults with diabetes post-kidney transplant Key takeaways: Adults with diabetes who underwent kidney transplantation had greater reductions in BMI and body weight if they used a GLP-1